Biocardia Inc is a biotechnology business based in the US. Biocardia Inc shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. Biocardia Inc employs 16 staff and has a trailing 12-month revenue of around $428,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.27 |
|---|---|
| 52-week range | $1.96 - $23.25 |
| 50-day moving average | $2.95 |
| 200-day moving average | $6.04 |
| Wall St. target price | $25.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-5.33 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.27 from 2024-09-06
| 1 week (2024-08-30) | -25.57% |
|---|---|
| 1 month (2024-08-09) | -15.30% |
| 3 months (2024-06-07) | -38.98% |
| 6 months (2024-03-08) | 439.06% |
| 1 year (2023-09-08) | 393.48% |
|---|---|
| 2 years (2022-09-09) | 18.85% |
| 3 years (2021-09-09) | 3.05 |
| 5 years (2019-09-09) | 4.8 |
| Revenue TTM | $428,000 |
|---|---|
| Gross profit TTM | $-7,482,000 |
| Return on assets TTM | -115.93% |
| Return on equity TTM | -703.62% |
| Profit margin | 0% |
| Book value | $-0.92 |
| Market Capitalization | $6.5 million |
TTM: trailing 12 months
We're not expecting Biocardia Inc to pay a dividend over the next 12 months.
Biocardia Inc's shares were split on a 1:15 basis on 29 May 2024. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocardia Inc shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Biocardia Inc shares which in turn could have impacted Biocardia Inc's share price.
Over the last 12 months, Biocardia Inc's shares have ranged in value from as little as $1.9562 up to $23.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocardia Inc's is 1.365. This would suggest that Biocardia Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioCardia, Inc. , a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.